Should Oncologists Be Aware in Their Clinical Practice of KRAS Molecular Analysis? Reply

被引：3

作者：

Benhaim, Leonor ^{[1
,2
]}

Maley, Karine ^{[1
,2
]}

Le Corre, Delphine ^{[1
,2
]}

Blons, Helene ^{[1
,2
]}

Laurent-Puig, Pierre ^{[1
,2
]}

Taly, Valerie ^{[3
,4
,5
]}

Bibeau, Frederic ^{[6
]}

Emile, Jean-Francois ^{[7
]}

机构：

[1] Paris Descartes Univ, Paris, France

[2] INSERM, UMR S775, Paris, France

[3] Inst Sci & Ingn Supramol, Strasbourg, France

[4] Univ Strasbourg, Strasbourg, France

[5] CNRS, UMR 7006, Strasbourg, France

[6] Ctr Reg Lutte Canc Val Aurelle, Montpellier, France

[7] Versailles St Quentin Yvelines Univ, Boulogne, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 08期

关键词：

COLORECTAL-CANCER; MUTATIONS; CARCINOMA;

D O I：

10.1200/JCO.2010.32.8799

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：E208 / E209

页数：2

共 11 条

[1] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[2]

BIBEAU F, 2010, J CLIN ONCOL S, V278, pS278

[3]

Carotenuto P, 2010, PHARMACOGENOMICS, V11, P1169, DOI [10.2217/pgs.10.86, 10.2217/PGS.10.86]

[4] K-ras mutations and benefit from cetuximab in advanced colorectal cancer [J].

Karapetis, Christos S. ;

Khambata-Ford, Shirin ;

Jonker, Derek J. ;

O'Callaghan, Chris J. ;

Tu, Dongsheng ;

Tebbutt, Niall C. ;

Simes, R. John ;

Chalchal, Haji ;

Shapiro, Jeremy D. ;

Robitaille, Sonia ;

Price, Timothy J. ;

Shepherd, Lois ;

Au, Heather-Jane ;

Langer, Christiane ;

Moore, Malcolm J. ;

Zalcberg, John R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (17) :1757-1765

[5] Targeted KRAS Mutation Assessment on Patient Tumor Histologic Material in Real Time Diagnostics [J].

Kotoula, Vassiliki ;

Charalambous, Elpida ;

Biesmans, Bart ;

Malousi, Andigoni ;

Vrettou, Eleni ;

Fountzilas, George ;

Karkavelas, George .

PLOS ONE, 2009, 4 (11)

[6] Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer [J].

Laurent-Puig, Pierre ;

Cayre, Anne ;

Manceau, Gilles ;

Buc, Emmanuel ;

Bachet, Jean-Baptiste ;

Lecomte, Thierry ;

Rougier, Philippe ;

Lievre, Astrid ;

Landi, Bruno ;

Boige, Valerie ;

Ducreux, Michel ;

Ychou, Marc ;

Bibeau, Frederic ;

Bouche, Olivier ;

Reid, Julia ;

Stone, Steven ;

Penault-Llorca, Frederique .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :5924-5930

[7] Sensitive Sequencing method for KRAS mutation detection by pyrosequencing [J].

Ogino, S ;

Kawasaki, T ;

Brahmandam, M ;

Yan, LY ;

Cantor, M ;

Namgyal, C ;

Mino-Kenudson, M ;

Lauwers, GY ;

Loda, M ;

Fuchs, CS .

JOURNAL OF MOLECULAR DIAGNOSTICS, 2005, 7 (03) :413-421

[8]

PEETERS M, 2010, J CLIN ONCOL S, V28, pS277

[9] Should Oncologists Be Aware in Their Clinical Practice of KRAS Molecular Analysis? [J].

Santini, Daniele ;

Galluzzo, Sara ;

Gaeta, Laura ;

Zoccoli, Alice ;

Riva, Elisabetta ;

Ruzzo, Annamaria ;

Vincenzi, Bruno ;

Graziano, Francesco ;

Loupakis, Fotios ;

Falcone, Alfredo ;

Muda, Andrea Onetti ;

Tonini, Giuseppe .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (08) :E206-E207

[10] High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue [J].

Tol, Jolien ;

Dijkstra, Jeroen R. ;

Vink-Borger, Marianne E. ;

Nagtegaal, Iris D. ;

Punt, Cornelis J. A. ;

van Krieken, Johan H. J. M. ;

Ligtenberg, Marjolijn J. L. .

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2010, 14 (08) :2122-2131

← 1 2 →